Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Lecture structure
- Basic facts about Alzheimer's disease
- The complexities of AD genetics
- Status of genetic association studies in AD
- The AlzGene database
- Top AlzGene results: significant by meta-analysis
- How real are the top results?
- Grading of epidemiologic credibility
- Applying the HuGENet guidelines to AlzGene
- Database for Parkinson's, schizophrenia and AD
- Current status of genetic studies
- Top genes for AD
- Four AlzGene's show association in AD families
- Variants in TF and ACE affect CSF A-beta levels
- The four AlzGene's are in the top results
- Candidate gene vs. GWAS studies
- Genome-wide association results in AD
- Three genes on the upper part of the list
- AlzGene meta-analysis for CLU (APOJ)
- AlzGene meta-analysis for CR1
- AlzGene meta-analysis for PICALM
- APOE (apolipoprotein E)
- CLU (clusterin [apolipoprotein J])
- GAB2 (GRB2-associated binding protein 2)
- ACE (angiotensin converting enzyme)
- CHRNB2 (beta2-cholinergic receptor, nicotinic)
- Summary: the complexities of AD genetics
- Outlook: what's next in AD genetics?
- Ultra high-throughput genetics technologies
- Applications of next-generation technologies
- Thirty years of Alzheimer's genetics - summary (1)
- Thirty years of Alzheimer's genetics - summary (2)
- Thirty years of Alzheimer's genetics - summary (3)
- Acknowledgements
Topics Covered
- Alzheimer's Disease
- Association studies in Alzheimer's Disease
- Systematic meta-analyses and risk loci
- Genome-wide association studies (GWAS)
- Potential functional relevance
- Next generation sequencing in Alzheimer's Disease
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Bertram, L. (2010, August 26). Thirty years of Alzheimer's genetics: what's new and what's next? [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 13, 2024, from https://doi.org/10.69645/PJEP4862.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Lars Bertram has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.